TCR cell therapies vanquish solid tumors — finally

Journal: Nature Biotechnology

Author: Charlotte Harrison, USA

This paper discusses the case of the first genetically modified T-cell therapy receiving FDA approval, successfully treating synovial sarcoma. Unlike CAR-T therapies, which have primarily been successful in blood cancers, TCR-T cell therapies are showing promise in solid tumors as well. Notably, the mechanism of recognizing and attacking intratumoral antigens has been enhanced, expected to usher in a new era of immunotherapy. Furthermore, research is ongoing to apply multiple T-cell therapies in a patient-specific manner.